Literature DB >> 3186211

Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure.

R David1, L Zangwill, M Badarna, Y Yassur.   

Abstract

A population-based study found an overall incidence rate of symptomatic retinal vein occlusion (RVO) in a 4-year period to be 2.14 per 1,000 in the 40 years and over age group. When cases found among glaucoma clinic patients were separated from the remainder of the population there was marked difference in the incidence rate of RVO in the same time period (1.85 and 17.3 per 1,000, respectively). The rate of RVO increased significantly (p less than 0.001) with age in the general population from 0.93 per 1,000 among persons under 64 years of age to 5.36 per 1,000 among persons over 65. The increase in the rate of RVO by age was less dramatic in the glaucoma clinic population. The two populations also differed in the frequency of the occlusion type: the ratio of the rate of branch vein occlusion to central vein occlusion was 3.2:1 in the general population, but equally distributed in the glaucoma clinic population. Persons with increased intraocular pressure and/or glaucoma were found to have a higher prevalence of RVO than persons with no history of elevated intraocular pressure.

Entities:  

Mesh:

Year:  1988        PMID: 3186211     DOI: 10.1159/000309923

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  37 in total

Review 1.  Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.

Authors:  Taygan Yilmaz; Miguel Cordero-Coma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-27       Impact factor: 3.117

2.  Prospective multicenter study of visual outcomes following three different treatments for macular edema associated with branch retinal vein occlusion: a study by the Japanese BRVO study group.

Authors:  Seiyo Harino; Kenichiro Bessho; Teruyo Kida
Journal:  Jpn J Ophthalmol       Date:  2012-02-23       Impact factor: 2.447

3.  Retinal vascular occlusions: an interdisciplinary challenge.

Authors:  Alireza Mirshahi; Nicolas Feltgen; Lutz L Hansen; Lars-Olof Hattenbach
Journal:  Dtsch Arztebl Int       Date:  2008-06-27       Impact factor: 5.594

4.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

Review 5.  [Differentiation of ocular hypertension].

Authors:  E M Hoffmann; J Lamparter
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

6.  [Arguments for prophylactic therapy of ocular hypertension].

Authors:  J Wahl
Journal:  Ophthalmologe       Date:  2011-11       Impact factor: 1.059

7.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

Review 8.  [Retinal vein occlusions].

Authors:  S Dithmar; L L Hansen; F G Holz
Journal:  Ophthalmologe       Date:  2003-07       Impact factor: 1.059

9.  Evaluation of ultrasound-assisted thrombolysis using custom liposomes in a model of retinal vein occlusion.

Authors:  Walid F Abdallah; Hitenkumar Patel; Edward G Grant; Bruno Diniz; Gerald J Chader; Mark S Humayun
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-05       Impact factor: 4.799

10.  Cardiovascular risk factors and outcome in patients with retinal vein occlusion.

Authors:  Mirko Di Capua; Antonio Coppola; Rosina Albisinni; Antonella Tufano; Anna Guida; Matteo Nicola Dario Di Minno; Ferdinando Cirillo; Marcello Loffredo; Anna Maria Cerbone
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.